Response Genetics, Inc (RGDXQ)

Market Cap	78.00 +100.0%
Revenue (ttm)	16.62M -8.1%
Net Income	-14.21M
EPS	-0.37
Shares Out	38.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,000
Open	0.0001
Previous Close	0.0001
Day's Range	n/a
52-Week Range	0.000001 - 0.0001
Beta	5.37
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Response Genetics

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, Respo...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 100
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGDXQ

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error